WEBULL
WebtradeDownload

Regeneron Q2 FY26 GAAP EPS falls 5% to $12.23; revenue rises 17% to $4.3 billion

PUBT · 2d ago
Regeneron Q2 FY26 GAAP EPS falls 5% to $12.23; revenue rises 17% to $4.3 billion
  • Regeneron Q2 2026 revenue rose 17% to $4.29 billion; GAAP EPS slipped 5% to $12.23.
  • Sanofi collaboration revenue climbed 51% to $2.17 billion on higher antibody commercialization profits tied to Dupixent sales.
  • U.S. EYLEA HD net sales jumped 52% to $596 million; U.S. EYLEA net sales fell 45% to $412 million.
  • Libtayo global net sales increased 30% to $489 million; Dupixent global net sales, recorded by Sanofi, rose 38% to $6 billion.
  • Non-GAAP EPS increased 11% to $14.29; 2026 GAAP R&D guidance was tightened to $6.5-$6.64 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300630PRIMZONEFULLFEED9800656) on July 30, 2026, and is solely responsible for the information contained therein.